Ivermectin, Fenbendazole & Mebendazole for Cancer: 2026 Evidence Guide
A Master Guide & Reference — Evidence, Mechanisms, Clinical Trials, Case Series, Safety, and Protocols
Quick Answer
Ivermectin, fenbendazole, mebendazole, and niclosamide are antiparasitic drugs with laboratory and animal evidence of anticancer activity, plus a growing body of patient-reported case reports. None of the four is an approved or established cancer treatment. Mebendazole and niclosamide have gone further into human oncology trials than fenbendazole, but results remain mixed or inconclusive. This guide organizes the mechanistic evidence, clinical trial data, 760+ compiled case reports, safety findings, and the updated Joe Tippens Protocol into one evidence-tiered reference — with the regulatory and safety picture current as of September 2026.
Table of Contents
Front Matter
Part I — The Case for Drug Repurposing
- Chapter 1: Conventional Cancer Treatment and Its Limits
- Chapter 2: Repurposing Existing Drugs for Cancer
Part II — The Four Repurposed Agents
- Chapter 3: Ivermectin for Cancer
- Chapter 4: Fenbendazole and Mebendazole for Cancer
- Chapter 5: Niclosamide for Cancer
Part III — Evidence, Regulation & Safety
- Chapter 6: Case Series — 760+ Real-World Outcomes Across 31 Cancer Types
- Chapter 7: 2026 Regulatory & Safety Update
- Chapter 8: Evidence Tier Summary (CEBM)
Part IV — Practical Application
Back Matter
Introduction: The Joe Tippens Story
In 2016, Oklahoma businessman Joe Tippens was diagnosed with small-cell lung cancer that had already metastasized to his pancreas, liver, bladder, bones, and neck. Given the extent of the spread, doctors gave him only a few months to live.
Facing this grim prognosis, Tippens learned from a veterinarian about fenbendazole, an antiparasitic drug used in animals, after a scientist with terminal cancer had reportedly used it on her lab mice — and herself. With few remaining options, Tippens tried fenbendazole alongside his conventional treatment, taking 1 gram per day for three consecutive days each week, cycling after four days off, alongside Theracurmin (a bioavailable curcumin) and CBD oil. After three months, he was declared cancer-free.
His case gained widespread attention and became known as the Joe Tippens Protocol, sparking interest in fenbendazole and related drugs such as ivermectin, mebendazole, and niclosamide as potential adjunct cancer therapies.
This guide compiles the mechanistic, preclinical, and clinical evidence behind these four repurposed antiparasitic drugs — along with the case reports, the current regulatory picture, and the protocols people are actually using — into a single evidence-tiered reference. A balanced literature search reveals preliminary signals in small trials but underscores the need for rigorous validation before these can be considered proven cancer treatments. Recent research highlights ivermectin's synergy with immune checkpoint inhibitors in breast cancer models and mebendazole's combination with docetaxel in prostate cancer, illustrating the repurposing rationale (Nature, 2021; Nature, 2019).
Note for clinicians: Most supporting evidence comes from preclinical studies rather than randomized controlled trials (RCTs), partly because RCTs in this space are difficult to fund — a reality mainstream oncologists may reasonably view with skepticism. Many documented case reports involve patients with stage 4 cancers who had exhausted conventional options and lacked actionable mutations for targeted therapy, and who showed complete response, partial response, or stable disease after starting a repurposed drug. This population generally has very limited remaining options, and second or third opinions may not be fruitful since many oncologists are unfamiliar with integrative repurposing frameworks. Clinicians should weigh potential benefits against risks, obtain informed consent, and — per ASCO's May 2026 guidance discussed in Chapter 7 — recognize that use outside a clinical trial currently carries an unacceptable-risk designation from the specialty's leading professional body.
Part I — The Case for Drug Repurposing
Chapter 1: Conventional Cancer Treatment and Its Limits
Cancer remains one of the world's most significant health challenges. In 2020, an estimated 19.3 million people worldwide were diagnosed with cancer and approximately 10 million died of the disease — about one in six deaths globally. Survival has improved substantially for many cancer types: the overall 5-year survival rate for all U.S. cancers combined rose from roughly 49% in the 1970s to about 68% for patients diagnosed in the 2010s. These gains are uneven, however. Pancreatic cancer still carries only about a 12–13% five-year survival rate, and once a cancer has metastasized to distant organs, cure rates remain extremely low. Global projections estimate more than 35 million new cancer cases per year by 2050 — a roughly 77% increase from 2022 — driven by population aging, demographic shifts, and risk-factor exposure.
Limitations of Standard Therapies
Modern oncology's toolkit — surgery, chemotherapy, radiation, hormonal therapy, targeted drugs, and immunotherapy — has extended and cured many lives, but each modality carries real limits:
Chemotherapy attacks rapidly dividing cells non-selectively, so healthy tissue (bone marrow, gut lining, hair follicles) is damaged alongside the tumor, limiting tolerable doses. Resistance often develops over time, and chemotherapy alone rarely eradicates advanced metastatic disease.
Radiation therapy is highly effective locally, but collateral damage to surrounding tissue causes localized side effects, and it cannot reach cancer that has spread widely — useful mainly for palliation in metastatic disease, with a small long-term risk of secondary radiation-induced cancers.
Immunotherapy (checkpoint inhibitors, CAR-T) has produced dramatic, durable responses in a subset of patients, but only about 20–40% of patients respond to current agents, many relapse as tumors develop immune-evasion mechanisms, and severe immune-related adverse events (colitis, hepatitis, endocrine disorders) can occur. Cost also puts these therapies out of reach in many settings.
Even after remission, microscopic disease can survive initial therapy and later recur or metastasize — meaning advanced-cancer treatment is often not definitively curative with today's tools, and patients must balance aggressive treatment against toxicity and quality of life.
Patient-Driven Demand for Adjunctive Approaches
Facing incomplete success and harsh side effects from standard treatment, an estimated 70% of cancer patients use some form of complementary or alternative medicine alongside conventional care. Steve Jobs, diagnosed with a rare pancreatic cancer in 2003, initially explored special diets, acupuncture, and other alternative therapies before surgery — a widely cited example of this instinct to seek every possible option and reclaim a sense of control. Many patients are influenced by anecdotal success stories shared in patient communities, which accelerates interest in adjunct treatments but also raises real concerns, since not every "cancer cure" claim online is credible, and some unproven remedies can interfere with standard care.
Chapter 2: Repurposing Existing Drugs for Cancer
Cancer incidence continues to rise, including aggressive, treatment-resistant tumors such as triple-negative breast cancer, pancreatic adenocarcinoma, and glioblastoma. Despite advances in targeted therapy and immunotherapy, many patients still face limited effective options. Global oncology drug spending exceeded $150 billion in 2022, and new-drug approval remains slow — conditions that have pushed drug repurposing (finding new therapeutic uses for existing, already-approved drugs) forward as a way to accelerate development while reducing cost and safety risk.
Off-label prescribing — using an approved drug for a use beyond its approved indication — is legal for physicians in most jurisdictions, based on clinical judgment when approved options are limited, though specifics vary by country and require careful consideration of evidence, risk, and informed consent.
The Mebendazole Discovery
The origin story often cited for this field involves Dr. Gregory Riggins, a neurosurgeon at Johns Hopkins, who in 2011 was studying medulloblastoma in mice implanted with malignant tumor cells. When his mice developed a pinworm infection, he treated them with the antiparasitic mebendazole — and the mice's tumors unexpectedly stopped growing. Riggins went on to study mebendazole as a potential anticancer agent; preliminary work suggested activity against leukemia, lymphoma, lung cancer, colon cancer, and brain tumors including glioblastoma and medulloblastoma, with a substantially better safety profile than vincristine, the standard chemotherapy for pediatric brain tumors that shares mebendazole's microtubule-blocking mechanism (Hope, 2020).
The UK's Care Oncology Clinic, now running glioblastoma trials, published preliminary retrospective data from the METRICS study (NCT02201381) in Frontiers in Pharmacology (2019) on 95 patients who added metformin, doxycycline, atorvastatin, and mebendazole to standard treatment — reporting average glioblastoma survival rising from roughly 15 to 27 months.
Antiparasitic Drugs as Cancer Agents: An Overview
Among repurposed candidates, antiparasitic drugs — fenbendazole, mebendazole, ivermectin, and more recently niclosamide — have attracted attention for demonstrated anticancer activity across preclinical models and a growing body of clinical case reports. Originally developed for helminth infections, they exert multifaceted effects on cancer cells: disrupting microtubule dynamics, interfering with metabolism, and modulating oncogenic signaling.
- Fenbendazole disrupts microtubule assembly, arrests the cell cycle at G2/M, and impairs glucose metabolism by blocking GLUT1/4 transporters and hexokinase — starving glycolysis-dependent cancer cells (the Warburg effect). It has shown activity against chemotherapy-resistant cell lines.
- Mebendazole shares fenbendazole's core mechanisms but offers better oral bioavailability, a longer human-use history, and blood-brain-barrier penetration relevant to brain tumors.
- Ivermectin works through a broader set of molecular targets — STAT3, Wnt/β-catenin, AKT/mTOR — inducing apoptosis, autophagy, and oxidative stress while targeting cancer stem cells and the tumor microenvironment, with activity reported across 20+ cancer types preclinically.
- Niclosamide is FDA-approved and inhibits Wnt/β-catenin, STAT3, mTORC1, NF-κB, and Notch signaling simultaneously while acting as a mitochondrial uncoupler. Its main clinical limitation is poor oral bioavailability.
Despite encouraging preclinical and anecdotal evidence, all four agents remain largely experimental in oncology, with limited randomized controlled trials and no cancer-specific regulatory approval. Their low cost, oral administration, and multi-targeted activity make them attractive candidates for further study — especially in resource-limited settings — but that attractiveness has not yet translated into proven clinical benefit.
Related: Top 30 Alternative Cancer Treatments That Work: Evidence-Based (2026 Edition)
Part II — The Four Repurposed Agents
Chapter 3: Ivermectin for Cancer
Mechanisms of Action
Ivermectin, FDA-approved since 1987 for parasitic infections such as onchocerciasis and administered to nearly 250 million people annually with a strong safety record, has drawn scientific interest for its anticancer properties — over 20 cancer types have shown susceptibility in laboratory and animal studies. Its transition into clinical oncology has been slowed largely by its off-patent, low-cost status, which reduces pharmaceutical incentive for expensive trials.
Reported mechanisms include inhibition of proliferation via Akt/mTOR, Wnt/β-catenin, and MAPK signaling; induction of apoptosis, autophagy, and pyroptosis; targeting of cancer stem cells; enhanced immunogenic cell death via P2X7; suppression of metastasis through PAK1 and RNA helicase inhibition; mitochondrial dysfunction with selective ROS increase in cancer cells; anti-angiogenic effects; epigenetic modulation via SIN3 domain interactions (restoring tamoxifen sensitivity); and reduction of multi-drug resistance. See the underlying primary literature in Ivermectin's Anti-Cancer Mechanisms: 9 Papers.
| Pathway/Target | Cancer Types Studied | Reported Mechanism |
|---|---|---|
| Akt/mTOR | Glioblastoma, renal cancer, leukemia | Inhibits mitochondrial function; induces oxidative stress and DNA damage |
| Wnt/β-catenin | Glioblastoma, colon, melanoma, breast, skin, lung | Inhibits proliferation and cancer-stem-cell formation |
| PAK1 | Glioblastoma, ovarian, breast, lung | Promotes autophagy; inhibits migration/invasion |
| P2X7 receptor | Triple-negative breast cancer | Enhances immunogenic cell death |
| SIN3 domain | Breast cancer | Restores sensitivity to tamoxifen |
| NS3 helicase | Glioma | Inhibits RNA helicase activity |
| YAP1 | Hepatocellular, cholangiocarcinoma, colorectal, ovarian, gastric | Suppresses tumor progression |
| Mitochondrial function | Multiple, incl. glioblastoma, leukemia | Selectively raises ROS in cancer cells |
| Angiogenesis | Various | Blocks new blood vessel formation |
| MDR reversal | Various | Enhances chemosensitivity |
Preclinical Evidence
In vitro and animal studies have reported ivermectin activity against bladder, breast, brain, bile duct, blood, bone, colon, cervical, CML, lung, glioma, multiple myeloma, ovarian, prostate, pancreatic, melanoma, liver, stomach, esophageal, and kidney cancer models, with animal-study tumor volume reductions ranging from roughly 50% to 85% depending on cancer type and dosing. A representative selection: bladder cancer (Fan et al., 2024), glioblastoma (Liu et al., 2016), gemcitabine-resistant cholangiocarcinoma (Intuyod et al., 2019), and hepatocellular carcinoma synergy with sorafenib (Lu et al., 2022), among many others cataloged in the underlying mechanisms review.
Clinical Evidence
Formal human trials remain limited but are growing:
- Hulscher et al. (2026) — a peer-reviewed prospective observational study of ivermectin plus mebendazole enrolled 197 total patients, 122 with at least six months of follow-up. This study is now the subject of a published Expression of Concern; see Chapter 7 for details.
- NCT05318469 (Cedars-Sinai, Yuan et al.) — a Phase I/II trial of ivermectin combined with balstilimab or pembrolizumab in metastatic triple-negative breast cancer, currently recruiting with an estimated enrollment of 34–41 patients and an estimated primary completion date of October 2026. Interim 2025 ASCO-presented data from this trial reported 1 partial response, 1 stable disease, and 6 progressive disease among 8 evaluable patients, with the combination described as "safe and well tolerated." This is early, small-cohort, single-arm data — encouraging as a safety signal, but not evidence of established efficacy.
- ICONIC Trial (NCT07487805) — a newer Phase II trial pairing ivermectin with an existing checkpoint inhibitor across solid tumors, sponsored by the University of Florida. As of this update the trial is listed as not yet recruiting.
- Case reports describe tumor-marker reductions in advanced colon, ovarian, gallbladder, and prostate cancers with high-dose ivermectin regimens (up to 2 mg/kg daily); see the network's 300+ case compilation and 750+ case compilation.
No serious adverse effects have been reported in healthy volunteers at doses up to 2 mg/kg, supporting ivermectin's general safety margin for further study — though safety at approved antiparasitic doses does not establish safety or efficacy at the higher, more frequent doses used in cancer self-treatment (see Chapter 7).
Dosing Discussed in the Literature and Patient Community
Safe dosing up to 2 mg/kg orally has been established for antiparasitic use, with peak plasma levels around 4 hours post-dose and an 18–19 hour half-life. Anecdotal cancer-focused regimens circulating in patient communities use daily or every-other-day dosing at or near 2 mg/kg — a level neither validated nor approved for oncology use. Ivermectin shows preclinical synergy with chemotherapy agents such as paclitaxel and gemcitabine.
Drug Interaction Warning
Ivermectin significantly amplifies the anticoagulant effect of warfarin (Coumadin) and may interact with other blood thinners. Patients on anticoagulants should be closely monitored by a physician before and during use.
Chapter 4: Fenbendazole and Mebendazole for Cancer
Mechanisms of Action
Fenbendazole is a veterinary antiparasitic (brand names include Panacur and Safe-Guard) in the benzimidazole class, which also includes mebendazole, albendazole, and flubendazole. Fenbendazole is approved only for veterinary use; mebendazole is FDA-approved for human intestinal-parasite treatment (brands Vermox and Emverm). Both have drawn scientific and public attention for anticancer activity against triple-negative breast cancer, colon cancer, glioma, and leukemia models, with the ketogenic diet sometimes proposed as an enhancer of their effects.
Fenbendazole's proposed mechanisms include microtubule disruption causing mitotic arrest and apoptosis; downregulation of GLUT1 and hexokinase II, starving glycolysis-dependent cells; caspase-mediated apoptosis and gasdermin-mediated pyroptosis; increased ROS promoting ferroptosis; G2/M cell-cycle arrest; proteasomal inhibition; immune modulation of the tumor microenvironment; and activity against chemotherapy-resistant cells (including 5-fluorouracil- and paclitaxel-resistant lines). These have been demonstrated across lung, ovarian, colorectal, cervical, breast, and lymphoma models in vitro and in vivo.
Preclinical and Clinical Evidence
Animal and cell studies report fenbendazole reducing tumor volume in lung cancer xenografts, inducing apoptosis in colorectal and breast cancer cells, and inhibiting glucose uptake. Human evidence remains largely anecdotal: case reports from over 180 patients using fenbendazole (often combined with ivermectin) describe tumor regression, though without controlled validation — see the 300+ case compilation and 700+ case compilation. A peer-reviewed case series, Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients (2025, Case Reports in Oncology), documents self-administration outcomes. Because fenbendazole lacks human clinical trials, most of what is known about the benzimidazole class in oncology trials comes from mebendazole.
Mebendazole, chemically and pharmacologically related to fenbendazole but with a much longer human-use record, has shown in research: reduced tumor growth and metastasis via cancer-stem-cell suppression in triple-negative breast cancer models; interest from Johns Hopkins researchers as a pancreatic-cancer adjuvant; blood-brain-barrier penetration relevant to brain tumors; and Phase 1/2 human trials in advanced gastrointestinal cancers and pediatric brain tumors — though pharmacokinetic limitations (poor and variable absorption) have constrained clinical responses in several trials.
Fenbendazole vs. Mebendazole
| Factor | Fenbendazole | Mebendazole |
|---|---|---|
| Human approval | Veterinary only — not FDA-approved for humans | FDA-approved (Vermox, Emverm) for intestinal parasites |
| Cost | Significantly less expensive | Higher cost, though compounded formulations are available |
| Clinical trial data | None in oncology; preclinical and anecdotal only | Phase 1/2 oncology trials conducted, with mixed results |
| Reported efficacy signal | Preclinical only | Possibly stronger for brain, prostate, and ovarian cancer per some preclinical work |
Dosing Discussed in the Literature and Patient Community
Fenbendazole regimens circulating in patient communities often use intermittent dosing (e.g., 3 days on, 4 days off) to reduce liver stress, though some users report tolerating daily dosing. Mebendazole dosing in oncology trials has ranged from 100 mg twice daily up to 4 g per day, with higher doses generally tolerated but limited clinical response in several trials, possibly reflecting the drug's pharmacokinetic limitations.
Safety, Side Effects, and Toxicity
Fenbendazole is generally considered low-toxicity based on limited human data, though it is not FDA-approved for human use. Studies cited in patient-facing sources suggest single doses up to 2,000 mg, or 500 mg per day for 10 days, are generally tolerated — but these are not validated oncology dosing guidelines and vary by individual. Up to about 5% of users report stomach discomfort or diarrhea at high, uninterrupted doses. Patients with severe liver or kidney impairment clear the drug more slowly and may need divided dosing; prolonged, uninterrupted use can cause reversible, asymptomatic liver-enzyme elevation. A baseline liver panel (AST, ALT, alkaline phosphatase) before starting, and a comprehensive metabolic panel after roughly one month, are commonly recommended in the patient-community literature — along with taking at least one day off per week during prolonged use. Co-administration with metronidazole may cause severe adverse reactions and should be avoided. See Chapter 7 for newly reported hepatotoxicity case data that update this picture.
Chapter 5: Niclosamide for Cancer
Background
Niclosamide is an FDA-approved antihelminthic first developed by Bayer in the late 1950s and approved for human use in 1962 (brand name Yomesan), used safely for decades against intestinal tapeworm infections. Unlike fenbendazole, it already carries human approval — a meaningful head start for off-label oncology exploration. High-throughput drug-screening campaigns have repeatedly flagged niclosamide as a potent anticancer compound; a 2025 review in the European Journal of Medicinal Chemistry described it as a multi-targeted therapeutic agent with effects across drug-resistant leukemia, ovarian, colorectal, prostate, and oral cancers. Its main clinical barrier is poor oral bioavailability — standard tablets do not reliably reach the serum concentrations needed for systemic anticancer effect, an active area of formulation research.
Mechanisms of Action
Niclosamide's anticancer profile is unusually broad, simultaneously disrupting multiple oncogenic networks: Wnt/β-catenin inhibition via LRP6 co-receptor degradation; STAT3 inhibition, reducing proliferation and enhancing treatment sensitivity; mTORC1 inhibition, impairing protein synthesis in rapidly dividing cells; NF-κB inhibition, promoting cancer-cell death; Notch inhibition, relevant to preventing recurrence via cancer-stem-cell suppression; mitochondrial uncoupling — its most distinctive mechanism, dissipating the proton gradient to deprive cancer cells of ATP while normal cells appear more tolerant; cancer-stem-cell inhibition, among the most potent identified in screening programs; ferroptosis induction via multiple mechanisms (Mathew et al., 2024); EMT inhibition, reducing migration and invasion; and reversal of multidrug resistance in resistant leukemia and ovarian cancer models.
Cancer Types with Preclinical Evidence
Colorectal cancer is the most studied indication — niclosamide suppresses Wnt/β-catenin-driven metastasis via S100A4 and inhibits xenograft tumor growth, work that led directly to the NIKOLO clinical trial. Other preclinical signals span castration-resistant prostate cancer (via androgen-receptor splice-variant and FOXM1 inhibition), breast cancer (including TNBC via ferroptosis and STAT3 inhibition), platinum-resistant ovarian cancer, oral squamous cell carcinoma, multidrug-resistant leukemia, and more limited data in lung, pancreatic, and hepatic cancers. Reported IC50 values for most tested cell lines are below 1 μM — theoretically accessible with improved formulations, though difficult to reach with standard oral dosing today.
Clinical Trials
| Trial | Cancer / Phase | Result |
|---|---|---|
| NIKOLO (NCT02519582) | Metastatic colorectal, Phase II | 2 g/day oral niclosamide; confirmed biological rationale but highlighted pharmacokinetic challenges reaching therapeutic systemic levels with oral tablets |
| NCT02687009 | Resectable colon cancer, Phase I | Terminated early due to low accrual |
| NCT02532114 | Castration-resistant prostate cancer + enzalutamide, Phase I | Max tolerated dose 500 mg three times daily; plasma levels did not consistently reach the preclinical efficacy threshold; no PSA decline observed; closed early by the Data Safety Monitoring Board |
Hyundai Bioscience announced a 2024 clinical development plan for an oral niclosamide anticancer formulation targeting p53-mutant cancers; no additional public trial results tied to that program are confirmed as of this September 2026 update. The overall clinical picture is that unmodified oral niclosamide does not reliably reach anticancer plasma concentrations, redirecting research toward novel salt forms (niclosamide ethanolamine, niclosamide piperazine), prodrug derivatives (e.g., PDMX1001), nanotechnology-based delivery, and alternative routes such as rectal suppositories that may bypass first-pass hepatic metabolism.
Dosing and Safety
Standard antiparasitic dosing (typically 2 g as a single dose, or 2 g/day for several days) is well tolerated but does not reach anticancer plasma concentrations with conventional tablets. The oncology-trial maximum tolerated dose has been 500 mg three times daily — still pharmacokinetically insufficient for most tumor types. Pediatric antiparasitic dosing (0.3–1.2 mg/kg/day) has an excellent safety record. Niclosamide's safety profile, developed over 60+ years of antiparasitic use, shows minimal side effects (mainly mild GI symptoms) at standard doses and generally acceptable tolerability even at the higher oncology-trial doses. Its poor bioavailability is, paradoxically, also a safety buffer: systemic exposure at standard oral doses stays low, limiting off-target effects.
Key consideration: Niclosamide's main challenge is not toxicity but efficacy — reaching tumor concentrations high enough to activate its anticancer mechanisms with standard oral administration. Formulation improvements are the critical next step before it can be meaningfully incorporated into clinical protocols.
Part III — Evidence, Regulation & Safety
Chapter 6: Case Series — 760+ Real-World Outcomes Across 31 Cancer Types
Snapshot (last full network audit, August 2026): 760+ total patient-reported and physician-reported cases compiled across 31 distinct cancer subtypes; three primary agents represented (fenbendazole, ivermectin, mebendazole); roughly 70% of cases involve Stage III–IV disease.
Companion case-series pages across this network have continued to add reports since this dataset was last fully audited. The table below reflects the last complete audit and should be read as a lower-bound anecdotal snapshot rather than a validated clinical registry — see each subtype's full sub-article for its current running count.
| # | Cancer Type | Signal Strength | Link |
|---|---|---|---|
| 1 | Brain / Glioblastoma | Strong | Read |
| 2 | Prostate Cancer | Strong | Read |
| 3 | Breast Cancer | Strong | Read |
| 4 | Colorectal Cancer | Strong | Read |
| 5 | Lung Cancer | Moderate | Read |
| 6 | Pancreatic Cancer | Moderate | Read |
| 7 | Lymphoma | Moderate | Read |
| 8 | Bladder / Kidney (Urological) | Moderate | Read |
| 9 | Esophageal / Gastric | Moderate | Read |
| 10 | Ovarian Cancer | Moderate | Read |
| 11 | Head & Neck | Moderate | Read |
| 12 | Skin Cancer / Melanoma | Moderate | Read |
| 13 | Leukemia | Early | Read |
| 14 | Liver / Bile Duct | Early | Read |
| 15 | Multiple Myeloma | Early | See main article |
| 16 | Sarcoma | Early | See main article |
| 17 | Uterine / Endometrial & Cervical | Early | Read |
| 18 | Thyroid Cancer | Early | Read |
| 19 | Other (PEComa, thymus, testicular, MDS, etc.) | Limited data | See main article |
A Real-World Utilization Data Point
Beyond self-published case reports, a chart review presented at the 2026 ASCO Gastrointestinal Cancers Symposium found 182 self-reported fenbendazole users among 297,223 patient visits at a single major U.S. cancer center, using at least 138 different self-devised dosing schedules — a useful independent signal that off-label use is real and widespread, and a reminder of how unstandardized and physician-invisible actual dosing patterns often are.
Interpretation Note
These case accounts are observational. Complete responses (CR/NED) in Stage IV cancer after prior chemotherapy failure are rare events in conventional oncology, making even small clusters of reported complete responses noteworthy as hypothesis-generating signals — but they do not constitute proof of efficacy and should not replace standard-of-care oncology. Confounding, publication bias, and survivorship bias are all acknowledged limitations of this dataset.
Chapter 7: 2026 Regulatory & Safety Update
This chapter is new to the September 2026 revision of this guide and consolidates the regulatory and research-integrity developments that most directly affect how the evidence in Chapters 3–6 should be read.
The ASCO Clinical Notice (May 2026)
In May 2026, ASCO — the largest professional body of oncologists in the United States — published a formal Clinical Notice addressing ivermectin and fenbendazole in cancer directly, prompted by a surge in patients self-medicating with these agents after exposure to social-media testimonials. Its core conclusions:
- There is no robust, peer-reviewed clinical evidence that ivermectin or fenbendazole is safe or effective for treating any human malignancy.
- ASCO strongly cautions that neither drug should be used to treat cancer, or as an adjunct to established cancer therapy, outside the regulatory safeguards of a well-designed clinical trial.
- The combination of unproven benefit and documented potential for toxicity and drug interaction represents, in ASCO's language, an unacceptable risk to patients.
- Fenbendazole is not FDA-approved for human use under any indication; ivermectin is FDA-approved only for specific parasitic infections, at doses well below those used in cancer self-treatment regimens.
This notice does not name mebendazole or niclosamide specifically, but the underlying rationale — insufficient controlled human evidence relative to the doses and durations being self-administered — applies to the broader repurposing landscape discussed in this guide.
Hulscher et al.: Expression of Concern and Disclosed Conflict of Interest
The largest published human observational cohort on ivermectin plus mebendazole in cancer — Hulscher et al., 197 enrolled patients with 122 followed for at least six months — now carries a formal Expression of Concern from its publishing journal, Anticancer Research (2026;46(6):e3243), issued by the journal's editorial board in June 2026 over data-integrity and ethical-verification issues. The paper's authorship also carries a disclosed financial conflict of interest connected to The Wellness Company, whose affiliate products are referenced elsewhere in the patient-protocol literature (including in Chapter 9 of this guide). Readers should treat this cohort as hypothesis-generating rather than confirmatory, and should weigh the conflict-of-interest disclosure when assessing how the data has been characterized in secondary sources.
Newly Reported Hepatotoxicity Cases
Case-report literature published since the prior version of this guide has added to the safety picture:
- A 2026 case report described a patient who developed severe hepatocellular injury — ALT over 1,700 U/L and bilirubin near 13 mg/dL — after combining ivermectin and fenbendazole on the advice of an online cancer support group.
- A separate case involved a 47-year-old woman with metastatic colon cancer on dual checkpoint-inhibitor immunotherapy who developed severe hepatocellular injury (RUCAM score of 8, "probable" fenbendazole causality) following a fenbendazole dose increase; immunotherapy was safely restarted once fenbendazole was discontinued. Additional cholestatic and hepatocellular injury cases have been reported in patients with hepatocellular carcinoma or cirrhosis and in patients on cemiplimab.
These reports reinforce the liver-monitoring guidance in Chapter 4 and underline why self-directed dose escalation — the pattern implicated in several of these cases — carries real risk, particularly for patients already on hepatically-cleared cancer therapies.
Publication Integrity
Separately, a previously published fenbendazole cancer case series was retracted in January 2026. Readers relying on any specific case-series publication in this space are encouraged to check the publisher's current status page for that article, since this field has seen more than one retraction or correction as scrutiny has increased in 2026.
Chapter 8: Evidence Tier Summary (CEBM)
The table below grades the strongest available human evidence for each agent using the Oxford Centre for Evidence-Based Medicine (CEBM) framework, where Level 1 is a systematic review of randomized trials and Level 5 is mechanism-based reasoning or expert opinion. No agent in this guide has reached Level 1 or a confirmatory Level 2 randomized trial for a cancer indication.
| Agent | Preclinical Evidence | Strongest Human Evidence | CEBM Level | Regulatory Status (Cancer) |
|---|---|---|---|---|
| Ivermectin | Extensive — 20+ cancer types in vitro/in vivo | Small single-arm Phase I/II trial (NCT05318469, ongoing); uncontrolled observational cohort (Hulscher et al., now under Expression of Concern); case reports | Level 4 (case series / uncontrolled cohort) | Not approved; ASCO caution (May 2026) |
| Fenbendazole | Substantial in vitro/in vivo, multiple mechanisms | Case reports and small self-administration case series only; no human oncology trials | Level 4–5 (case reports / mechanistic) | Veterinary-only; not human-approved; ASCO caution (May 2026) |
| Mebendazole | Substantial, overlaps with fenbendazole | Phase 1/2 human oncology trials (GI cancers, pediatric brain tumors); mixed/limited responses, pharmacokinetic constraints | Level 2 (small uncontrolled/early-phase trials) | FDA-approved for parasites; not approved for cancer |
| Niclosamide | Broad, multi-pathway mechanisms; strong cancer-stem-cell data | Phase I/II oncology trials (NIKOLO, NCT02687009, NCT02532114); inconclusive/negative, largely due to bioavailability | Level 2 (Phase I/II trials, negative/inconclusive) | FDA-approved for parasites; not approved for cancer |
Reading this table plainly: mebendazole and niclosamide have been tested in actual human oncology trials and have not yet shown a clear efficacy signal, largely for different reasons (mebendazole's variable absorption, niclosamide's poor bioavailability). Ivermectin has more case-report volume and one small ongoing safety/dose-finding trial, but its largest observational dataset is compromised. Fenbendazole has the least human data of the four and remains, at this stage, primarily a laboratory and case-report story.
Part IV — Practical Application
Chapter 9: The Updated Joe Tippens Protocol
The following is a modernized version of the original Joe Tippens protocol, updated to incorporate the ivermectin- and mebendazole-based regimen published in the Journal of Orthomolecular Medicine (2024). It combines repurposed antiparasitic drugs with evidence-supported nutraceuticals. As covered in Chapter 7, ASCO's May 2026 guidance applies directly to the ivermectin and fenbendazole/mebendazole components of this protocol — it should be reviewed with, not instead of, an oncology team.
- Ivermectin — 25–50 mg daily (6 days per week), or up to 1 mg/kg/day for aggressive or advanced cancers. Take with a high-fat meal to maximize absorption.
- Mebendazole — 250–500 mg daily (6 days per week). Alternatively, fenbendazole at 222 mg six days per week, with doses up to 1 gram per day discussed for aggressive cancers.
- Vitamin D — 62.5 mcg (2,500 IU) daily, seven days a week.
- Bio-available curcumin — 600 mg per day, 7 days a week.
- Enhanced-absorption berberine — 500 mg per day, to help limit glucose availability to cancer cells.
- Diet and lifestyle: eliminate or sharply limit added sugars (a 2023 BMJ umbrella review recommends keeping free/added sugars below 25 g/day and sugar-sweetened beverages to fewer than one per week); follow a whole-food diet and minimize ultra-processed foods (per 2024 BMJ guidelines); prioritize adequate sleep and effective stress management.
Protocol notes:
- Vitamin E was removed from the protocol (Joe Tippens, July 2020) due to interactions with blood thinners.
- Ivermectin significantly increases warfarin's blood-thinning effect and may interact with other anticoagulants — patients on blood thinners should be closely monitored by a physician.
- This protocol is not a replacement for standard oncology care. It is designed as an adjunct strategy to complement, not replace, conventional treatment, and — per Chapter 7 — its ivermectin and fenbendazole/mebendazole components currently fall outside ASCO's recommended use conditions when used outside a clinical trial.
Conclusion and Future Directions
Ivermectin, fenbendazole, mebendazole, and niclosamide have each emerged from the antiparasitic toolkit as compelling candidates for drug repurposing in cancer. Their ability to disrupt cancer-cell metabolism, induce multiple forms of cell death, and address drug resistance offers hope for affordable, accessible treatment options. Double-blind, prospective RCTs remain the gold standard, but they are costly and slow — and N=1 trials, open-label studies, and real-world data offer practical, if less rigorous, alternatives that can still generate valuable hypotheses, particularly for rare or advanced cancers, so long as their limitations (no control group, potential bias) are kept in view.
For patients with Stage 4 or aggressive cancers with few remaining options, the "right to try" carries genuine moral weight — but as ASCO's May 2026 notice makes clear, that weight does not currently translate into a green light for unsupervised, outside-of-trial use of ivermectin or fenbendazole. A personalized clinical approach — integrating empirical evidence, clinical observation, and objective markers such as tumor markers and imaging — can function as a series of monitored N=1 trials, ideally conducted with, not around, an oncology team.
Fenbendazole and ivermectin are not magic bullets, and cancer rarely yields to one or two interventions however determined. True empowerment comes from multi-layered strategy — keeping the conversation open with clinicians experienced in metabolic and repurposing approaches.
What is still needed: optimized formulations of niclosamide to achieve reliable therapeutic plasma concentrations (the single biggest bottleneck to its clinical translation); well-designed randomized or pragmatic trials suited to advanced-cancer complexity for all four agents; research into combination regimens with immunotherapy and metabolic interventions (ketogenic diets, GLP-1 agonists); mechanistic work on drug-resistant tumors and the tumor microenvironment; and investigation of complementary, non-overlapping synergies between niclosamide and the benzimidazoles. These are legitimate scientific questions deserving legitimate scientific resources — and, as the evidence continues to grow, so does the obligation to weigh it honestly, including the regulatory and integrity findings covered in Chapter 7.
Ask an AI Assistant About This Guide
This page is structured so AI assistants such as Claude, ChatGPT, Gemini, and Perplexity can answer follow-up questions accurately from it. If you're using one of these tools, you can paste this page's link and ask things like:
- "Summarize the current human clinical trial evidence for ivermectin in cancer from this article."
- "What does ASCO's May 2026 notice say, and how does it apply to the Joe Tippens Protocol described here?"
- "Build me a CEBM evidence-tier comparison table for these four drugs based on this guide."
Because the underlying evidence is still evolving quickly in 2026, ask your AI assistant to run a fresh web search on any specific trial (by NCT number) or publication before treating a figure as current — and always bring specific protocol questions to a physician familiar with your case, not to an AI assistant alone.
Frequently Asked Questions
Important: Fenbendazole, ivermectin, mebendazole, and niclosamide are not established standard-of-care cancer treatments. Much of the evidence discussed in this guide comes from laboratory studies, animal research, case reports, and observational data rather than randomized controlled oncology trials. None of this should replace surgery, radiation, chemotherapy, targeted therapy, immunotherapy, hormone therapy, or other evidence-based treatment recommended by a qualified oncology team.
Understanding the Four Drugs
Are ivermectin, fenbendazole, mebendazole, and niclosamide interchangeable?
No. Although all four are antiparasitic drugs that have attracted interest as potential repurposed cancer therapies, they differ in molecular targets, mechanisms, absorption and metabolism, tissue distribution, human safety data, approved uses, drug-interaction profiles, and the strength of evidence behind them. Mebendazole and fenbendazole are structurally related benzimidazoles; ivermectin belongs to a different class (avermectins); niclosamide is a salicylanilide. Mechanisms may overlap in laboratory settings, but overlap does not mean equivalence — evidence for one drug cannot simply be transferred to another. See the Cancer Biomarker Map for Fenbendazole, Mebendazole and Ivermectin for a deeper mechanistic comparison.
Why are fenbendazole and mebendazole often discussed together?
They are both benzimidazole-class antiparasitics sharing structural and pharmacologic features, which has led researchers to ask whether mechanisms seen with one apply to the other. But being in the same drug class does not make them clinically equivalent. Mebendazole has far more human clinical experience since it is an established human antiparasitic; fenbendazole is primarily a veterinary drug. Mebendazole's human safety and pharmacokinetic history should not be used to justify fenbendazole use.
Can ivermectin be substituted for mebendazole, fenbendazole, or niclosamide?
No — they should not be treated as simple substitutes. Even where two drugs appear to affect a similar pathway in the lab, their tumor concentration, metabolism, toxicity, and achievable human exposure can differ substantially. The clinically relevant question isn't whether a compound has an interesting mechanism — it's whether that specific drug, at a clinically achievable exposure, improves outcomes for a specific cancer. That question remains unresolved for all four agents discussed here.
Does combining these drugs make treatment stronger?
It is not established that combining them produces a better clinical outcome. There may be theoretical reasons to investigate combinations where preclinical studies suggest complementary pathways, but theoretical synergy is not demonstrated clinical synergy. Combining multiple repurposed drugs also makes it harder to determine which compound is producing an effect or causing an adverse event, and whether drug interactions alter exposure. Combination strategies should be evaluated through properly designed clinical research, not assumed superior on mechanism alone.
Can evidence for one of these drugs be used as evidence for another?
Not directly. A positive laboratory study, trial, or case report involving one compound should be attributed to that compound, not generalized to a related one — and the same applies in reverse. This distinction matters most in cancer repurposing research, where mechanistic similarity can tempt excessive extrapolation. A useful comparison always asks: what drug, what cancer, what mechanism, what dose or exposure, what evidence level, what clinical endpoint, what confounders? That framing lets you distinguish "antiparasitic drugs deserve investigation in general" from "this particular drug benefits patients with this particular cancer."
Can these drugs be accurately called "anticancer drugs"?
Not at present. A more accurate description is that they are antiparasitic drugs being investigated or discussed for potential anticancer applications. Calling them established anticancer drugs implies a level of clinical evidence and regulatory acceptance that does not currently exist for any of the four.
Which of the four has the strongest human clinical foundation?
They have different evidence profiles, summarized in the Chapter 8 evidence tier table. Ivermectin and mebendazole have extensive human experience for their approved indications, but investigational status in cancer. Mebendazole and niclosamide have actually been tested in human oncology trials, with mixed or inconclusive results tied to pharmacokinetic limitations. Fenbendazole has the least human clinical experience of the four because it remains veterinary-only. Having more general human safety experience with one drug should not be read as evidence of anticancer efficacy for that drug.
Efficacy & Safety Basics
Can fenbendazole or ivermectin cure cancer?
No. There is currently insufficient high-quality clinical evidence to conclude that fenbendazole or ivermectin can cure cancer. Individual case reports can be scientifically interesting and hypothesis-generating, but they cannot establish that a drug caused a remission — patients in these reports often also received conventional treatment, other repurposed drugs, supplements, or dietary interventions, any of which could affect the outcome.
Why are these drugs being studied in cancer at all?
Laboratory studies have identified plausible anticancer mechanisms — effects on cell-cycle regulation, cytoskeletal function, cellular metabolism, oxidative stress, apoptosis, autophagy, intracellular signaling, and tumor-immune interactions, depending on the drug and experimental model. These findings generate biological hypotheses, but activity in cultured cells or animal models does not automatically translate into effective human treatment.
Is fenbendazole approved for human use?
No. Fenbendazole is a veterinary antiparasitic drug and is not FDA-approved as a human cancer treatment. Human safety, pharmacokinetics, optimal dosing, and anticancer efficacy have not been established to the standard required for an approved oncology therapy.
Is ivermectin approved for cancer?
No. Ivermectin is an established human antiparasitic medicine for specific approved indications, but cancer treatment is not an approved indication, and its potential anticancer effects remain investigational.
What is the strongest human evidence for ivermectin in cancer?
A 2026 prospective observational cohort (Hulscher et al.) reported outcomes in patients receiving ivermectin plus mebendazole, but the study was not randomized, included substantial patient-reported outcome data, and its publication now carries an Expression of Concern over data-integrity and ethical-verification issues along with a disclosed author conflict of interest — see Chapter 7. A small, ongoing Phase I/II trial (NCT05318469) has reported early safety and modest response signals. This evidence should be regarded as hypothesis-generating, not proof of effectiveness.
What is the strongest human evidence for fenbendazole?
Human evidence for fenbendazole is particularly limited — published case reports and small self-administration case series describe patients who took fenbendazole alongside other treatments and later experienced remission or disease control. These may generate research questions, but cannot determine whether fenbendazole caused the response.
Should these drugs be used instead of standard cancer treatment?
No. Patients should not stop or delay evidence-based cancer treatment because of claims about fenbendazole, ivermectin, mebendazole, niclosamide, or any other repurposed drug. Appropriate treatment depends on cancer type, stage, biomarkers, prior treatment, overall health, and the patient's goals — decisions that belong with a qualified oncology team.
Are the doses discussed online proven cancer doses?
No. Doses circulated through patient communities or published anecdotal protocols should not be treated as validated oncology dosing. Human clinical trials are needed to establish appropriate oncology dosing for any of these agents.
What are the main safety concerns?
Safety depends on the specific drug, dose, formulation, duration, the patient's liver and kidney function, other medications, and the underlying cancer. Ivermectin, mebendazole, and niclosamide have established human uses for certain parasitic infections, but that does not establish safety or efficacy when used experimentally, at higher doses, or for longer durations in cancer. Fenbendazole has substantially less human safety information because it is not an approved human medicine. Newly reported hepatotoxicity cases (Chapter 7) reinforce that potential drug interactions and organ toxicity should be reviewed by a qualified clinician, not inferred from anecdotal reports.
Does laboratory evidence mean these drugs work in people?
No. Cancer cells in a laboratory dish are not equivalent to tumors inside a human body. Drug concentration, absorption, metabolism, tissue penetration, tumor heterogeneity, immune response, toxicity, and drug resistance can all affect whether a laboratory finding becomes clinically useful.
What does ASCO say about using these drugs for cancer?
In a May 2026 Clinical Notice, ASCO stated there is no robust, peer-reviewed clinical evidence that ivermectin or fenbendazole is safe or effective for treating any human malignancy, and strongly cautioned against using either outside a registered clinical trial. See Chapter 7 for the full notice summary.
Where does the evidence stand today?
There is substantial mechanistic and preclinical interest across all four drugs, an expanding collection of human case reports and observational data, and continuing interest in drug repurposing — but the evidence remains insufficient to establish any of the four as a standard cancer treatment. The critical next step is rigorous, independently verified clinical research, conducted with the regulatory safeguards ASCO's notice describes.
OneDayMD Evidence Note
The presence of a published study, case report, testimonial, or mechanistic finding does not mean a treatment has been proven effective. We distinguish between Preclinical evidence → Human observational evidence → Case reports/series → Randomized clinical evidence. These evidence categories answer different questions and should not be treated as interchangeable — the Chapter 8 CEBM table above applies this framework across all four drugs covered in this guide.
Medical Disclaimer
This guide is provided for educational and research purposes only and is not personal medical advice. Fenbendazole, ivermectin, mebendazole, and niclosamide should not be used to replace or delay evidence-based cancer treatment. Discuss any off-label or investigational therapy with an appropriately qualified healthcare professional, and review the ASCO Clinical Notice in Chapter 7 before considering off-label use of ivermectin or fenbendazole outside a registered clinical trial.
Affiliate Disclosure: This page contains affiliate links. Products from The Wellness Company are linked using referral code ONEDAYMD, and Amazon products are linked using Associates tag df2021-20. We may earn a commission on qualifying purchases made through these links, at no additional cost to you. This does not change our evaluation of the underlying evidence, and inclusion of a product link is not an endorsement of unsupervised off-label cancer use.
The Wellness Company's Ivermectin and Mebendazole — both approved for human use, researched and reviewed by Dr. Peter McCullough; prescribed by licensed medical professionals, compounded and dispensed by a licensed U.S.-based pharmacy, lab-tested for potency, with doctor consultation included and free U.S. shipping. Available at The Wellness Company's website.
.png)
Comments
Post a Comment